<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03105219</url>
  </required_header>
  <id_info>
    <org_study_id>NFH20170403</org_study_id>
    <nct_id>NCT03105219</nct_id>
  </id_info>
  <brief_title>IvaBradinE to Treat MicroalbumiNuria in Patients With Type 2 Diabetes and Coronary Heart Disease</brief_title>
  <acronym>BENCH</acronym>
  <official_title>IvaBradinE to Treat MicroalbumiNuria in Patients With Type 2 Diabetes and Coronary Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing First Hospital, Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing First Hospital, Nanjing Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To explore the efficacy of Ivabradine for the treatment of microalbuminuria in patients with&#xD;
      type 2 diabetes and coronary heart disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, randomized, open-label, investigator-initiated study with a parallel&#xD;
      design. Patients with type 2 diabetes and coronary heart disease who are microalbuminuric&#xD;
      [urinary albumin excretion (UAE): 30-500 mg/day], will be randomized after informed consent,&#xD;
      in a 1:1 ratio to the following treatment groups: Group Α: Ivabradine 5mg twice a day (on day&#xD;
      0), heart rate evaluated at day 14 and 28 repeatedly, and the targeted value of heart rate&#xD;
      50-60bpm, the largest dosage 7.5mg twice a day.&#xD;
&#xD;
      Group Β: Placebo. Urinary albumin excretion (UAE) assessment will be performed before&#xD;
      randomization (Day 0), 28-day after randomization (Day 28), and 90-day after randomization&#xD;
      (Day 28).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Shortfall in funding&#xD;
  </why_stopped>
  <start_date type="Anticipated">July 1, 2017</start_date>
  <completion_date type="Anticipated">May 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Urinary albumin excretion at 3 month</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary albumin excretion</measure>
    <time_frame>3 month</time_frame>
    <description>Urinary albumin excretion at 3 month</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum creatinine</measure>
    <time_frame>3 month</time_frame>
    <description>Serum creatinine at 3 month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood urea nitrogen</measure>
    <time_frame>3 month</time_frame>
    <description>Blood urea nitrogen at 3 month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cyscatin-c</measure>
    <time_frame>3 month</time_frame>
    <description>Cyscatin-c at 3 month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypersensitive c-reactive protein (hsCRP)</measure>
    <time_frame>3 month</time_frame>
    <description>Hypersensitive c-reactive protein (hsCRP) at 3 month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>β2-microglobulin</measure>
    <time_frame>3 month</time_frame>
    <description>β2-microglobulin at 3 month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutrophil gelatinase-associated lipocalin(NGAL)</measure>
    <time_frame>3 month</time_frame>
    <description>Neutrophil gelatinase-associated lipocalin(NGAL) at 3 month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albuminuria and urine creatinine ratio (ACR)</measure>
    <time_frame>3 month</time_frame>
    <description>Albuminuria and urine creatinine ratio (ACR) at 3 month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>N-acyl-β-D-glucosidase</measure>
    <time_frame>3 month</time_frame>
    <description>N-acyl-β-D-glucosidase at 3 month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinol binding protein</measure>
    <time_frame>3 month</time_frame>
    <description>Retinol binding protein at 3 month</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Diabetic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Ivabradine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ivabradine 5mg twice a day (on day 0), heart rate evaluated at day 14 and 28 repeatedly, and the targeted value of heart rate 50-60bpm, the largest dosage 7.5mg twice a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Comparator</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Urinary albumin excretion (UAE) assessment will be performed before randomization (Day 0), 28-day after randomization (Day 28), and 90-day after randomization (Day 28).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivabradine</intervention_name>
    <description>Ivabradine 5mg twice a day (on day 0), heart rate evaluated at day 14 and 28 repeatedly, and the targeted value of heart rate 50-60bpm, the largest dosage 7.5mg twice a day.</description>
    <arm_group_label>Ivabradine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham Comparator</intervention_name>
    <description>Urinary albumin excretion (UAE) assessment will be performed before randomization (Day 0), 28-day after randomization (Day 28), and 90-day after randomization (Day 28).</description>
    <arm_group_label>Sham Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Type 2 diabetes and coronary heart disease;&#xD;
&#xD;
          -  2. Urinary albumin excretion: 30-500mg/24h;&#xD;
&#xD;
          -  3. Sinus rhythm, and resting heart rate ≥ 70bpm;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Renal dysfunction defined as eGFR &lt; 30ml/min/1.73m^2;&#xD;
&#xD;
          -  2. Atrial flutter, and atrial fibrillation;&#xD;
&#xD;
          -  3. Resting heart rate &lt; 70bpm;&#xD;
&#xD;
          -  4. Combined with non-dihydropyridine CCB;&#xD;
&#xD;
          -  5. UAE&lt;30mg/24h, or &gt; 500mg/24h;&#xD;
&#xD;
          -  6. Acute heart failure;&#xD;
&#xD;
          -  7. Low blood pressure (BP&lt;90/50mmHg);&#xD;
&#xD;
          -  8. Acute myocardial infarction (&lt;14 days);&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shaoliang Chen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Nanjing First Hospital, Nanjing Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nanjing First Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>April 3, 2017</study_first_submitted>
  <study_first_submitted_qc>April 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 7, 2017</study_first_posted>
  <last_update_submitted>November 5, 2020</last_update_submitted>
  <last_update_submitted_qc>November 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanjing First Hospital, Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>Shaoliang Chen</investigator_full_name>
    <investigator_title>Vice President</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

